Perturbations in the levels of prostacyclin and/or of the prostacyclin receptor (IP) have been associated with a host of pathologies including thrombosis, stroke, ischemic heart disease, systemic and pregnancy-induced hypertension [5–7]. This evidence concerns the gene PTGIR and stroke disorder.